Premature polyadenylation of MAGI3 is associated with diminished N6-methyladenosine in its large internal exon

In cancer, tumor suppressor genes (TSGs) are frequently truncated, causing their encoded products to be non-functional or dominant-negative. We previously showed that premature polyadenylation (pPA) of MAGI3 truncates the gene, switching its functional role from a TSG to a dominant-negative oncogene. Here we report that MAGI3 undergoes pPA at the intron immediately downstream of its large internal exon, which is normally highly modified by N6-methyladenosine (m6A). In breast cancer cells that upregulate MAGI3pPA, m6A levels in the large internal exon of MAGI3 are significantly reduced compared to cells that do not express MAGI3pPA. We further find that MAGI3pPA transcripts are significantly depleted of m6A modifications, in contrast to highly m6A-modified full-length MAGI3 mRNA. Finally, we analyze public expression data and find that other TSGs, including LATS1 and BRCA1, also undergo intronic pPA following large internal exons, and that m6A levels in these exons are reduced in pPA-activated breast cancer cells relative to untransformed mammary cells. Our study suggests that m6A may play a role in regulating intronic pPA of MAGI3 and possibly other TSGs, warranting further investigation.

[1]  Christopher B. Burge,et al.  Promoter directionality is controlled by U1 snRNP and polyadenylation signals , 2013, Nature.

[2]  Yang Wang,et al.  N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells , 2014, Nature Cell Biology.

[3]  S. Berget Exon Recognition in Vertebrate Splicing (*) , 1995, The Journal of Biological Chemistry.

[4]  W. ElShamy,et al.  Identification of BRCA1-IRIS, a BRCA1 locus product , 2004, Nature Cell Biology.

[5]  広田 亨,et al.  Zyxin,a Regulator of Actin Filament Assembly,Targets the Mitotic Apparatus by Interacting with h-warts/LATS1 Tumor Suppressor , 2000 .

[6]  Charlotte Kuperwasser,et al.  Premature polyadenylation of MAGI3 produces a dominantly-acting oncogene in human breast cancer , 2016, eLife.

[7]  P. Miron,et al.  BRCA1-IRIS Overexpression Promotes Formation of Aggressive Breast Cancers , 2012, PloS one.

[8]  G. Rubin,et al.  Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Gideon Rechavi,et al.  Transcriptome-wide mapping of N6-methyladenosine by m6A-seq based on immunocapturing and massively parallel sequencing , 2013, Nature Protocols.

[10]  Larry N. Singh,et al.  U1 snRNP Determines mRNA Length and Regulates Isoform Expression , 2012, Cell.

[11]  W. ElShamy,et al.  BRCA1-IRIS overexpression abrogates UV-induced p38MAPK/p53 and promotes proliferation of damaged cells , 2010, Oncogene.

[12]  Larry N. Singh,et al.  U1 snRNP protects pre-mRNAs from premature cleavage and polyadenylation , 2010, Nature.

[13]  M. Kupiec,et al.  Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq , 2012, Nature.

[14]  Arne Klungland,et al.  A majority of m6A residues are in the last exons, allowing the potential for 3′ UTR regulation , 2015, Genes & development.

[15]  Chengqi Yi,et al.  N6-Methyladenosine in Nuclear RNA is a Major Substrate of the Obesity-Associated FTO , 2011, Nature chemical biology.

[16]  Samir Adhikari,et al.  Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase , 2014, Cell Research.

[17]  W. ElShamy,et al.  BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells. , 2006, Experimental cell research.

[18]  Gretchen A. Stevens,et al.  A century of trends in adult human height , 2016, eLife.

[19]  O. Elemento,et al.  Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop Codons , 2012, Cell.

[20]  Chuan He,et al.  N6-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions , 2015, Nature.

[21]  Chuan He,et al.  N 6 -methyladenosine Modulates Messenger RNA Translation Efficiency , 2015, Cell.

[22]  Marko Hočevar,et al.  A variant in FTO shows association with melanoma risk not due to BMI , 2013, Nature Genetics.

[23]  H. Saya,et al.  Tumor suppressor WARTS ensures genomic integrity by regulating both mitotic progression and G1 tetraploidy checkpoint function , 2004, Oncogene.

[24]  Chuan He,et al.  YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA , 2017, Cell Research.

[25]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[26]  F. Rottman,et al.  Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase. , 1997, RNA.

[27]  Patrick Neven,et al.  Genome-wide association studies identify four ER negative–specific breast cancer risk loci , 2013, Nature Genetics.

[28]  Tao Pan,et al.  RNA modifications and structures cooperate to guide RNA–protein interactions , 2017, Nature Reviews Molecular Cell Biology.

[29]  Xiaolong Yang,et al.  LATS tumor suppressor: A new governor of cellular homeostasis , 2010, Cell cycle.

[30]  Arne Klungland,et al.  ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. , 2013, Molecular cell.

[31]  W. Tao,et al.  Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity , 1999, Nature Genetics.

[32]  Miao Yu,et al.  A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation , 2013, Nature chemical biology.

[33]  N. Proudfoot Ending the message: poly(A) signals then and now. , 2011, Genes & development.